Semnur Pharmaceuticals Inc.

As of June 30, 2026, Semnur Pharmaceuticals Inc. carries a market capitalization of 115.10M, placing it among publicly traded companies globally. Its enterprise value stands at 138.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Semnur Pharmaceuticals Inc. has 230.21M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Semnur Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 0.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 0.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 138.12M versus a market cap of 115.10M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Semnur Pharmaceuticals Inc. maintains a current ratio of 0.11, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -77.68, indicating conservative leverage, while an interest coverage ratio of 1,246.18 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 2.75, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Semnur Pharmaceuticals Inc.'s stock has declined approximately 94.44% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Semnur Pharmaceuticals Inc. generated - - in revenue and converted that into -167.67M in net income, yielding earnings per share of -0.75. EBITDA reached 153.28M, while operating income came in at -167.55M.

As of June 30, 2026, Semnur Pharmaceuticals Inc. holds 39,000.00 in cash and equivalents against 23.05M in total debt, resulting in a net debt position of 23.01M. Total book value stands at -29.67M, with working capital of -9.48M providing operational flexibility.

Semnur Pharmaceuticals Inc. produced -10.54M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.15, meaning Semnur Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Semnur Pharmaceuticals Inc. has an Altman Z-Score of -493.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.